Logo

HUTCHMED Receives the Pharmacy and Poisons Board of Hong Kong’s Approval for Elunate (fruquintinib) to Treat Metastatic Colorectal Cancer (CRC)

Share this
HUTCHMED

HUTCHMED Receives the Pharmacy and Poisons Board of Hong Kong’s Approval for Elunate (fruquintinib) to Treat Metastatic Colorectal Cancer (CRC)

Shots:

  • The approval was granted by the PPBHK following the NMPA approval of Elunate based on the results from the P-III (FRESCO) trial. Fruquintinib (Fruzaqla) was also approved by the US FDA in Nov 2023 for CRC
  • The P-III (FRESCO) study evaluated the safety & efficacy of Elunate (n=278) vs PBO (n=138) in patients with metastatic CRC with OS as 1EP & PFS, ORR & DCR as 2EPs. The results from the trial depicted a mOS of 9.3mos. vs 6.6mos. & a mPFS of 3.7mos. vs 1.8mos.
  • Following the approval, Elunate will be marketed in Hong Kong by HUTCHMED whereas it has been developed & commercialized in mainland China in collaboration with Eli Lilly & Takeda has the exclusive license for areas outside mainland China, Hong Kong & Macau

Ref: HUTCHMED | Image: HUTCHMED

Related News:- HUTCHMED Reports the NDA Submission of Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions